Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Preferred Stock Liabilities (2019)

Beam Therapeutics (BEAM) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $302.0 million as the latest value for Q4 2019.

  • Quarterly Preferred Stock Liabilities changed N/A to $302.0 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $302.0 million through Dec 2019, changed N/A year-over-year, with the annual reading at $302.0 million for FY2019, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2019 was $302.0 million at Beam Therapeutics, up from $298.8 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $302.0 million in Q4 2019, with the low at $292.3 million in Q1 2019.